Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H) - Trial NCT06146946
Access comprehensive clinical trial information for NCT06146946 through Pure Global AI's free database. This phase not specified trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Not yet recruiting. The study focuses on Rectal Cancer. Target enrollment is 1384 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Timeline & Enrollment
N/A
Dec 01, 2023
Dec 01, 2029
Primary Outcome
3-year disease free survival rate
Summary
The goal of this clinical trial is to learn about whether it is safe to omit dissection of
 the No.253 lymph nodes in mid and low rectal cancer surgery. The main question it aims to
 answer is that if it is possible to achieve the same long-term survival with and without the
 dissection of the No.253 lymph node in mid and low rectal cancer surgery. Participants will
 underwent laparoscopic rectal radical resection with or without the dissection of the No.253
 lymph node.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06146946
Non-Device Trial